Angina Market Share

Global Angina Market Overview

Angina Market Size was valued at USD 0.52 Billion in 2023. The Global Angina industry is projected to grow from USD 0.72 Billion in 2024 to USD 2.13 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 5.52% during the forecast period (2024 - 2032).

Angina is a significant symptom of the coronary artery disease and is described as squeezing, tightness, and heaviness of the chest. It is a type of chest pain, which is caused by a reduced flow of blood to the heart. Fatigue, shortness of breath, nausea, and sweating are some of the common symptoms of angina. The increasing prevalence of angina and the growing healthcare expenditure are the major drivers for the market growth. According to the report of the American Heart Association of 2016, the prevalence of angina in West Virginia was estimated to be around 6.2% and around 2.3% in Hawaii. Moreover, the growing geriatric and obese population followed by the increasing prevalence of coronary heart diseases provide favorable backgrounds for market growth. 

According to the World Health Organization, the total number of people who age 65 or more is projected to increase from 524 million in 2010 to approximately 1.5 billion by 2050. Additionally, according to a study published in the Annals of Translational Medicine Journal approximately 15.5 million people who aged 20 years or more within the U.S. suffered from the coronary heart disease, in 2016. However, factors such as low per capita healthcare expenditure and high cost for therapeutic procedures such as coronary bypass surgery are estimated to restraint the market growth during the forecast period. According to a study published by the Brazilian Journal of Cardiovascular Surgery in 2017, the average total cost for coronary bypass surgery was estimated to be ~USD 7,992.

March 2024: Auxilius Pharma intends to file an investigational new drug (IND) application for AUX-001, with the aim of commencing a Phase Ib trial for chronic stable angina pectoris (CSAP). According to CEO Jed Litwiniuk, the business aims to commence the Phase Ib trial in either Q4 2024 or early Q1 2025, shortly after obtaining IND approval from the US Food and Drug Administration (FDA), as reported by the Clinical Trials Arena. Auxilius Pharma has developed AUX-001, a once-daily formulation of nicorandil specifically designed for patients suffering from chronic stable angina pectoris. AUX-001 is an orally administered, extended-release formulation of Roche's nicorandil, which was initially synthesized by Chugai Pharmaceutical. Chugai Pharmaceutical planned to introduce it to the United States. Roche purchased the firm but decided to discontinue the cardiovascular portfolio and hence disposed of the project. The Phase Ib trial will focus on bioequivalence research, specifically evaluating the pharmacokinetics of AUX-001 over a period of one month. The experiment will involve around 35 healthy volunteers. The study must demonstrate that the once-daily AUX-001 is pharmacokinetically equal to the twice-daily product.

February 2024: Zydus Lifesciences Ltd said that it has obtained final permission from the US health agency to produce and sell its generic Isosorbide Mononitrate extended-release tablets. These pills are intended to prevent chest discomfort in individuals with a certain cardiac ailment. Zydus Lifesciences has received approval from the US Food and Drug Administration (USFDA) to produce and sell Isosorbide Mononitrate Extended-Release in strengths of 30 mg, 60 mg, and 120 mg, according to a regulatory filing. Isosorbide mononitrate is administered to mitigate angina, a symptom of coronary artery disease, in patients with this specific heart condition. The product will be produced in the group's formulation manufacturing facility located in Ahmedabad SEZ.

Global Angina Market Segmentation

The angina market is segmented on the basis of type, diagnosis, treatment, and end-user.

On the basis of type, the market is segmented into angina pectoris, unstable angina, prinzmetal angina, and others. 

On the basis of diagnosis, the market is categorized into imaging, blood test, stress test, and others. The imaging segment is sub-segmented into electrocardiogram, chest X-ray, cardiac computerized tomography scan, cardiac MRI, and others. The blood test segment is sub-segmented into cholesterol test, low-density lipoprotein test, triglycerides test, and others. 

On the basis of treatment, the market is segmented into lifestyle changes, medications, angioplasty and stenting, coronary bypass surgery, and others. The medication segment is sub-segmented into aspirin, clot-preventing drugs, statins, ranolazine, and others. The clot-preventing drugs segment is further segmented into clopidogrel, prasugrel, and others. 

On the basis of end-user, the Angina Market is segmented into hospitals and clinics, diagnostic centers, academic institutes, and others.

Global Angina Market Regional Analysis

America dominates the angina market owing to a well-developed healthcare sector, growing healthcare expenditure, and a huge patient population for coronary heart diseases. Moreover, global players such as Merck & Co., Inc. and Baxter within the region fuel the market growth.

Europe is the second largest market for angina. Factors such as availability of funds for research, growing number of obese and patient population, followed by the presence of developed economies such as France, Italy, and Germany within the region provide favorable backgrounds for regional market growth. According to the Eurostat in 2016, it was estimated that more than half of the adult population (51.6%) within the European Union was over-weight.

Asia Pacific is estimated to be the fastest growing region for the angina market owing to the presence of developing economies such as India and China and a developing healthcare sector. Moreover, rising healthcare expenditure and favorable government policies are expected to boost the Angina Market growth during the forecast period.

The Middle East and Africa holds the least share in the angina market, owing to the presence of poor economies, stringent government policies, and low per capita healthcare expenditure, especially within the African region. A majority of the market of the region is held by the Middle East owing to the increasing healthcare expenditure and presence of developed economies such as Saudi Arabia, Kuwait, and Qatar within the region.

Key Players in the Angina Market

• Anthera (U.S.)


• Taxus Cardium (U.S.)


• Astellas Pharma (Japan)


• Sanofi (France)


• Bayer AG (Germany)


• Merck & Co., Inc. (U.S.)


• Torrent Pharmaceuticals Limited (India)


• Huya Bioscience International (U.S.)


• Viromed Co. Ltd. (South Korea)


• Baxter (U.S.)

Intended Audience

• Pharmaceutical Companies


• Biotechnological Institutes


• Research and Development (R&D) Companies


• Medical Research Laboratories


• Market Research and Consulting Service Providers